Otsuka (OTSKF) Stock Price, News & Analysis

Company Overview

Otsuka Holdings Co., Ltd., trading on OTC markets as OTSKF, is a global healthcare company headquartered in Tokyo, Japan. Established in 1964 as a research-driven pharmaceutical firm, Otsuka has since evolved into a diversified holding company overseeing operations in pharmaceuticals, nutraceuticals and consumer products. The company operates through a network of subsidiaries, including Otsuka Pharmaceutical Co., Ltd., Otsuka America Pharmaceutical, Inc., and Otsuka Europe, each focusing on drug development, manufacturing and distribution.

In its pharmaceutical division, Otsuka is best known for discovering and commercializing treatments in areas such as psychiatry, oncology and nephrology. Flagship products include aripiprazole (marketed jointly with global partners for psychiatric disorders) and tolvaptan, a therapy for hyponatremia and polycystic kidney disease. The nutraceutical segment leverages Otsuka’s research capabilities to develop functional foods and beverages, with brands such as SoyJoy nutrition bars and Pocari Sweat, an electrolyte beverage popular in Asia.

Otsuka maintains a strong global presence, conducting research, clinical trials and manufacturing across Asia, North America, Europe and emerging markets. The company’s international network includes research centers in Japan and the United States, as well as regional marketing and distribution offices in Europe, China, India and Latin America. This broad footprint supports Otsuka’s commitment to meeting diverse healthcare needs and bringing innovative therapies to patients worldwide.

Research and development remain central to Otsuka’s strategy, with investments in novel drug delivery systems, digital therapeutics and next-generation small molecules. Collaborations with academic institutions, biotechnology firms and public health organizations further bolster the company’s pipeline. Guided by a board of directors based in Tokyo, Otsuka continues to pursue sustainable growth through scientific innovation, strategic partnerships and a focus on patient-centric solutions.

Key Stats

• Today's Range: $44.40 to $44.40
• 50-Day Range: $44.40 to $50.73
• 52-Week Range: $44.40 to $66.15
• Volume: N/A
• Average Volume: 1,026 shs
• Market Capitalization: N/A
• P/E Ratio: 0.15
• Dividend Yield: 125.63%
• Price Target: N/A
• Consensus Rating: N/A

Otsuka Stock Analysis - MarketRank™

Otsuka scored higher than 16% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Otsuka.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Otsuka is 0.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.49.

Price to Earnings Ratio vs. Sector

The P/E ratio of Otsuka is 0.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.18.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Otsuka has a short interest ratio ("days to cover") of 3252, which indicates bearish sentiment.

Change versus previous month

Short interest in Otsuka has recently decreased by 19.41%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Otsuka pays a meaningful dividend of 3.45%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Otsuka does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Otsuka is 18.48%. This payout ratio is at a healthy, sustainable level, below 75%.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Otsuka has a short interest ratio ("days to cover") of 3252, which indicates bearish sentiment.

Change versus previous month

Short interest in Otsuka has recently decreased by 19.41%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.34

News Sentiment

Otsuka has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.94 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Otsuka this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Otsuka insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 12.20% of the stock of Otsuka is held by institutions.

OTSKF Stock Analysis - Frequently Asked Questions

How have OTSKF shares performed this year?

Otsuka's stock was trading at $57.15 at the start of the year. Since then, OTSKF shares have decreased by 22.3% and is now trading at $44.40.

How do I buy shares of Otsuka?

Shares of OTSKF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 9/15/2025
• Next Earnings (Estimated): 10/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - General
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:OTSKF
• CIK: 1544613
• Web: www.otsuka.com
• Phone: (136) 717-1410
• Fax: N/A
• Employees: 34,388
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.15
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A